The p53 Pathway in Glioblastoma
Путь p53 при глиобластоме
2018-09-01
SCID: 54.1/4u23uaad
Discuss with AI
TP53 mutationsgain-of-function p53 mutantsglioblastomap53 pathwayp53-ARF-MDM2 pathway
Figures from the paper
Abstract (AI)
The tumor suppressor and transcription factor p53 plays critical roles in tumor prevention by orchestrating a wide variety of cellular responses, including damaged cell apoptosis, maintenance of genomic stability, inhibition of angiogenesis, and regulation of cell metabolism and tumor microenvironment. TP53 is one of the most commonly deregulated genes in cancer. The p53-ARF-MDM2 pathway is deregulated in 84% of glioblastoma (GBM) patients and 94% of GBM cell lines. Deregulated p53 pathway components have been implicated in GBM cell invasion, migration, proliferation, evasion of apoptosis, and cancer cell stemness. These pathway components are also regulated by various microRNAs and long non-coding RNAs. TP53 mutations in GBM are mostly point mutations that lead to a high expression of a gain of function (GOF) oncogenic variants of the p53 protein. These relatively understudied GOF p53 mutants promote GBM malignancy, possibly by acting as transcription factors on a set of genes other than those regulated by wild type p53. Their expression correlates with worse prognosis, highlighting their potential importance as markers and targets for GBM therapy. Understanding mutant p53 functions led to the development of novel approaches to restore p53 activity or promote mutant p53 degradation for future GBM therapies.
Key Findings
1
Deregulated p53 pathway components contribute to glioblastoma invasion, migration, proliferation, apoptosis evasion, and cancer stemness.
2
Gain-of-function p53 mutants may promote glioblastoma malignancy by regulating genes distinct from those controlled by wild-type p53.
3
Glioblastoma TP53 alterations are predominantly point mutations producing highly expressed gain-of-function oncogenic p53 variants.
4
Mutant p53 expression correlates with poorer prognosis and supports therapeutic strategies aimed at restoring p53 activity or inducing mutant p53 degradation.
5
The p53-ARF-MDM2 pathway is deregulated in 84% of glioblastoma patients and 94% of glioblastoma cell lines.
Research Object
The p53 pathway in glioblastoma (GBM), including TP53 and its ARF–MDM2-regulated components and gain-of-function p53 mutants
Research Subject
Deregulation and oncogenic functions of the p53 pathway in GBM, including effects on malignancy, prognosis, and therapeutic targeting
Publication Details
Publication Date
2018-09-01
Journal
Publisher
ISSN
Cited by
466
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest